Several of these sites were substrates for CK2A, and we tested if long-term exposure to BRAFi provided protection from the synergistic inhibitory effects of protein kinase CK2A–BRAF co-inhibition previously observed in BRAF(V600E) mutant melanoma (43). The gene discussed is BRAF; the disease is melanoma.